Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 4/20 | 0.48 |
| ▸ | NOS2 | P35228 | 4/20 | 0.48 |
| ▸ | CCR1 | P32246 | 2/20 | 0.39 |
| ▸ | CCR5 | P51681 | 2/20 | 0.39 |
| ▸ | CCR8 | P51685 | 2/20 | 0.39 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | TTK | P33981 | 1/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14247814 | 0.88 | NOS3 (0.44) | NOS3NOS2CCR1CCR5CCR8 | |
| SCHEMBL4074890 | 0.79 | ALDH1A1 (0.44) | CCR1CCR5CCR8APLNRGAA | |
| SCHEMBL23624004 | 0.79 | CCR1 (0.38) | NOS3NOS2CCR1CCR5CCR8 | |
| SCHEMBL26361648 | 0.79 | MAOA (0.41) | NOS3NOS2CCR1CCR5CCR8 | |
| SCHEMBL16231386 | 0.77 | HPGD (0.50) | NOS3NOS2CCR1CCR5CCR8 | |
| SCHEMBL7899151 | 0.77 | AURKA (0.44) | NOS3NOS2CCR1CCR5CCR8 | |
| SCHEMBL5942324 | 0.77 | DRD1 (0.39) | NOS3NOS2CCR1CCR5CCR8 | |
| SCHEMBL22972330 | 0.77 | TRPA1 (0.37) | NOS3NOS2CCR1CCR5CCR8 | |
| SCHEMBL22928459 | 0.77 | CYP3A4 (0.37) | NOS3NOS2CCR1CCR5CCR8 | |
| SCHEMBL18686677 | 0.77 | SMN1; SMN2 (0.37) | NOS3NOS2CCR1CCR5CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024137671-A1 | COMPOUNDS THAT INHIBIT PKMYT1 | EXELIXIS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024105364-A1 | HETEROCYCLIC INHIBITORS OF CDC-LIKE KINASES | CURADEV PHARMA LTD (GB) | 2024-05-23 | — | — | WO | disclosed |
| EP-3956320-B1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH INC (US) | 2023-11-29 | — | — | EP | disclosed |
| US-20230322675-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LHOTSE BIO, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230257362-A1 | TRIAZOLONE COMPOUND | MEDSHINE DISCOVERY INC. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230257362-A1 | TRIAZOLONE COMPOUND | MEDSHINE DISCOVERY INC. (CN) | 2023-08-17 | — | — | US | disclosed |
| WO-2023141511-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY (US) | 2023-07-27 | — | — | WO | disclosed |
| EP-4079724-A1 | FUSED RING COMPOUND AND APPLICATION THEREOF | Wuhan LL Science and Technology Development Co., Ltd. (CN) | 2022-10-26 | — | — | EP | disclosed |
| WO-2022109001-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2021191359-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-30 | — | — | WO | disclosed |
| WO-2012055034-A1 | SULFONAMIDES AS HIV PROTEASE INHIBITORS | MERCK CANADA INC. (CA) | 2012-05-03 | — | — | WO | disclosed |
| US-20120065233-A1 | TYROSINE KINASE INHIBITORS | GREGOR VLAD EDWARD (US) | 2012-03-15 | — | — | US | disclosed |
| WO-2011059021-A1 | 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE | 大日本住友製薬株式会社 (JP) | 2011-05-19 | — | — | WO | disclosed |
| CN-100575345-C | 2 type Cannabined receptors are had in conjunction with active Pyridione derivatives | SHIONOGI & CO | 2009-12-30 | — | — | CN | disclosed |
| CN-1960975-A | Substituted pyridones as poly (ADP-ribose) polymerase (PARP) inhibitors | AVENTIS PHARMA INC (US) | 2007-05-09 | — | — | CN | disclosed |
| CN-1511140-A | Oxime ether compound and agricultural or horticultural bactericide | �ձ�������ʽ���� | 2004-07-07 | — | — | CN | disclosed |
| US-20040116480-A1 | Oxime ether compound and agricultural or horticultural bactericide | NIPPON SODA CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
| CN-1492856-A | Pyridone derivative having affinity for cannabinoid 2-type receptor | ��Ұ����ҩ��ʽ���� | 2004-04-28 | — | — | CN | disclosed |
| EP-1362850-A1 | OXIME ETHER COMPOUND AND AGRICULTURAL OR HORTICULTURAL BACTERICIDE | NIPPON SODA CO., LTD. (JP) | 2003-11-19 | — | — | EP | disclosed |
| CN-1085218-C | Olefin polymerization catalyst | ASAHI CHEMICAL IND (JP) | 2002-05-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322675-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LPAR2, LPAR1, LPAR6 | NOS3 4474/4885NOS2 4630/4885CCR1 1481/4885 |
| US-20230257362-A1 | TRIAZOLONE COMPOUND | WNK3, SLC10A1, WNK2 | NOS3 1405/4885NOS2 1528/4885CCR1 3371/4885 |
| US-20120065233-A1 | TYROSINE KINASE INHIBITORS | ALK, ROS1, ABL1 | NOS3 2903/4885NOS2 3406/4885CCR1 3965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.